RBA’s Bullock: Inflation likely to rise further in near term
Reserve Bank of Australia (RBA) Governor Michele Bullock testified on Thursday before the Senate Economics Legislation Committee.
Key quotes
Flow of data and developments since may has not been materially different to our expectations.
We expect inflation to increase further in the near term.
We will be carefully monitoring conditions to assess how the combined effects of higher interest rates and the energy price shock are playing out.
Having raised the cash rate three times, monetary policy is well placed to respond to developments.
Inflation is too high, and the board will do what it considers necessary to achieve our mandate to deliver price stability and full employment.
We’ve already seen some signs that this tightening is starting to work, though it will take around 1 to 2 years for the effects to fully flow through the economy.
Conditions in the housing market have eased in recent months and that partly reflects tighter monetary policy.
Market reaction
At the time of writing, the AUD/USD pair is trading 0.02% lower on the day to trade at 0.7127.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Alphabet (GOOGL.US) Launches Roadshow for HKD and SGD Bond Issuance; May Become a "Touchstone" for Investor Confidence Amid AI Market Volatility
Alphabet (GOOGL.US) has launched the roadshow for its first Hong Kong dollar and Singapore dollar bond issuance, aiming to test investor subscription interest as companies focused on artificial intelligence (AI) face increased market volatility.

Euro finds temporary support near 1.1066 against US Dollar, outlook remains uncertain
Strategy (MSTR.US) officially removed from the MSCI index—what does this mean for crypto-related stocks?
Strategy has been officially removed from the MSCI index, with passive funds facing exit pressure. Crypto-related stocks are experiencing "significant" selling pressure.

Biotech Insider Trading in US Stocks Diverges: ImmunityBio (IBRX.US) Cashes Out the Most, Sellas (SLS.US) Director Bought In Before a 5x Surge
Insider trading in US-listed biotech companies shows divergence.
